List view / Grid view
Dr Rob van Montfort, a leading researcher at the Centre for Cancer Drug Discovery (CCDD) within The Institute of Cancer Research, London, is at the forefront of cancer drug discovery. Focusing on protein-ligand interactions, his work utilises structural biology and biochemical methods to help the discovery of novel small-molecule drugs…
20 October 2023 | By Eurofins Discovery
Watch this webinar to learn how biophysics can be used in different cascade strategies where the goal is to identify and characterise fragments, compounds or active degraders targeting PIM3 kinase.
In an exclusive interview with Nikki Carter at Molecular Devices, we explore the the power of patient-derived organoids (PDOs) in drug discovery.
Researchers have achieved profound insights into the inner workings of a prevalent environmental bacterium.
Sino Biological are pleased to announce the formal opening of its new center for Bioprocessing (C4B) in Houston, Texas USA at Levit Green, adjacent to the world-renowned Texas Medical Center.
4 October 2023 | By Halo Labs
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
Read this guide about nanoDSF for high-resolution measurements of thermal stability parameters, common CQAs for biologics developability assessment.
Human derived induced pluripotent stem cells (hiPSCs) have revolutionised research and are increasingly used for toxicology screening and disease modelling. Early detection of neurotoxicity induced by potential new therapies is a major challenge, and hiPSC-neuronal cells may provide a solution. These cells demonstrate considerable promise for uncovering drug-induced perturbations to…
![In experiments in rats and mice, two Johns Hopkins scientists -- an engineer and an ophthalmologist -- report the successful use of nanoparticles to deliver gene therapy for blinding eye disease. A uniquely engineered large molecule allows researchers to compact large bundles of therapeutic DNA to be delivered into the cells of the eye [credit: John Hopkins Medicine].](https://www.drugtargetreview.com/wp-content/uploads/nanoparticle-gene-therapy-blindness-image.jpg)
This article discusses the need for adulticidal drugs to treat Onchocerca volvulus infections, a parasite causing onchocerciasis (river blindness), as the current treatment with ivermectin and surgery presents challenges for affected communities. It highlights research findings on the potential of analgesic medicines to target adult worms and emphasises the importance…
Stability attributes of biologic candidates are evaluated during early development workflows. Learn how to measure them with biophysical techniques.
We are thrilled to announce the winner of the Drug Target Review x ELRIG's Article Competition: Dr Rosa Woldegebriel, Lead Scientist at the Human Centric Drug Discovery in Oxford, UK, whose article titled "Advancing Drug Discovery for Pain Disorders: Human iPSC-Based Approach" presents a revolutionary method in pharmaceutical research. Addressing…
In an exclusive interview, Dr Neville Sanjana, Associate Professor of biology at NYU and a core faculty member at the New York Genome Center, discusses the breakthrough study on STING-seq.
25 July 2023 | By Eurofins Discovery
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
Researchers from Tokyo Tech's World Research Hub Initiative conducted a study to investigate the regulation of gene expression in the apicoplast of the malaria parasite Plasmodium falciparum.
In this interview with Drug Target Review’s Izzy Wood and Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, discuss the innovative potential of condensate biology in revolutionising drug discovery. By targeting disease-driving condensates, Dewpoint’s research pushes boundaries by offering new hope for tackling diseases like ALS and colorectal cancer.
